Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 43

Cited In for PubMed (Select 21999779)

1.

Factors Associated with Timing of Initiation of Antiretroviral Therapy among HIV-1 Infected Adults in the Niger Delta Region of Nigeria.

Ogoina D, Finomo F, Harry T, Inatimi O, Ebuenyi I, Tariladei WW, Afolayan AA.

PLoS One. 2015 May 1;10(5):e0125665. doi: 10.1371/journal.pone.0125665. eCollection 2015.

2.

Adaptive pair-matching in randomized trials with unbiased and efficient effect estimation.

Balzer LB, Petersen ML, van der Laan MJ; SEARCH Consortium.

Stat Med. 2015 Mar 15;34(6):999-1011. doi: 10.1002/sim.6380. Epub 2014 Nov 25.

PMID:
25421503
3.

Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidence.

Eaton JW, Hallett TB.

Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):16202-7. doi: 10.1073/pnas.1323007111. Epub 2014 Oct 13.

4.

Modeling the implementation of universal coverage for HIV treatment as prevention and its impact on the HIV epidemic.

Ying R, Barnabas RV, Williams BG.

Curr HIV/AIDS Rep. 2014 Dec;11(4):459-67. doi: 10.1007/s11904-014-0232-x.

5.

Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia.

Yirdaw KD, Jerene D, Gashu Z, Edginton ME, Kumar AM, Letamo Y, Feleke B, Teklu AM, Zewdu S, Weiss B, Ruff A.

PLoS One. 2014 Aug 8;9(8):e104557. doi: 10.1371/journal.pone.0104557. eCollection 2014.

6.

Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011.

Nosyk B, Montaner JS, Yip B, Lima VD, Hogg RS; STOP HIVAIDS Study Group.

Med Care. 2014 Apr;52(4):362-9. doi: 10.1097/MLR.0000000000000097.

7.

Global HIV epidemiology: A guide for strategies in prevention and care.

Vermund SH.

Curr HIV/AIDS Rep. 2014 Jun;11(2):93-8. doi: 10.1007/s11904-014-0208-x.

8.

Mortality and causes of death among HIV-infected individuals in the country of Georgia: 1989-2012.

Chkhartishvili N, Sharvadze L, Chokoshvili O, Bolokadze N, Rukhadze N, Kempker RR, Gamkrelidze A, DeHovitz JA, Del Rio C, Tsertsvadze T.

AIDS Res Hum Retroviruses. 2014 Jun;30(6):560-6. doi: 10.1089/AID.2013.0219. Epub 2014 Feb 24.

9.

Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease.

Périssé AR, Smeaton L, Chen Y, La Rosa A, Walawander A, Nair A, Grinsztejn B, Santos B, Kanyama C, Hakim J, Nyirenda M, Kumarasamy N, Lalloo UG, Flanigan T, Campbell TB, Hughes MD; P E A R L S study team of the ACTG.

PLoS One. 2013 Dec 31;8(12):e83643. doi: 10.1371/journal.pone.0083643. eCollection 2013.

10.

Concentrated HIV subepidemics in generalized epidemic settings.

Tanser F, de Oliveira T, Maheu-Giroux M, Bärnighausen T.

Curr Opin HIV AIDS. 2014 Mar;9(2):115-25. doi: 10.1097/COH.0000000000000034. Review.

11.

Modelling the strategic use of antiretroviral therapy for the treatment and prevention of HIV.

Ford N, Hirnschall G.

PLoS Med. 2013 Oct;10(10):e1001535. doi: 10.1371/journal.pmed.1001535. Epub 2013 Oct 22.

12.

Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?

Cohen MS, Smith MK, Muessig KE, Hallett TB, Powers KA, Kashuba AD.

Lancet. 2013 Nov 2;382(9903):1515-24. doi: 10.1016/S0140-6736(13)61998-4. Epub 2013 Oct 23. Review.

13.

Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access.

Jain V, Byonanebye DM, Liegler T, Kwarisiima D, Chamie G, Kabami J, Petersen ML, Balzer LB, Clark TD, Black D, Thirumurthy H, Geng EH, Charlebois ED, Amanyire G, Kamya MR, Havlir DV; SEARCH Collaboration.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):327-32. doi: 10.1097/QAI.0000000000000021.

14.

HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011.

Nosyk B, Min J, Lima VD, Yip B, Hogg RS, Montaner JS; STOP HIV/AIDS Study Group.

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):653-9. doi: 10.1097/QAI.0b013e3182976891.

15.

Steps towards preventive HIV treatment in Fujian, China: problems identified via an assessment of initial antiretroviral therapy provision.

Xia P, Okumura J, Yan P, Xie M, Wu S, Zhuang M, Zheng J, Zhang C, Zhang M, Kato M, Cai G, Yamamoto T.

PLoS One. 2013 Sep 24;8(9):e76483. doi: 10.1371/journal.pone.0076483. eCollection 2013.

16.

The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study.

Nosyk B, Montaner JS, Colley G, Lima VD, Chan K, Heath K, Yip B, Samji H, Gilbert M, Barrios R, Gustafson R, Hogg RS; STOP HIV/AIDS Study Group.

Lancet Infect Dis. 2014 Jan;14(1):40-9. doi: 10.1016/S1473-3099(13)70254-8. Epub 2013 Sep 27.

17.

Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches.

Suthar AB, Ford N, Bachanas PJ, Wong VJ, Rajan JS, Saltzman AK, Ajose O, Fakoya AO, Granich RM, Negussie EK, Baggaley RC.

PLoS Med. 2013 Aug;10(8):e1001496. doi: 10.1371/journal.pmed.1001496. Epub 2013 Aug 13. Review.

18.

Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality.

Corbett EL, MacPherson P.

Int J Tuberc Lung Dis. 2013 Sep;17(9):1125-38. doi: 10.5588/ijtld.13.0117. Review.

19.

Outcomes and impact of HIV prevention, ART and TB programs in Swaziland--early evidence from public health triangulation.

van Schalkwyk C, Mndzebele S, Hlophe T, Garcia Calleja JM, Korenromp EL, Stoneburner R, Pervilhac C.

PLoS One. 2013 Jul 26;8(7):e69437. doi: 10.1371/journal.pone.0069437. Print 2013.

20.

When to start antiretroviral therapy: the need for an evidence base during early HIV infection.

Lundgren JD, Babiker AG, Gordin FM, Borges ÁH, Neaton JD.

BMC Med. 2013 Jun 14;11:148. doi: 10.1186/1741-7015-11-148.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk